Your Support Addresses an Urgent Community Need: CRI Lends

FALL 2 0 13
ACCESS
A publication of Community Research Initiative of New England
I n si d e A C C E S S
CRI Lends HIV Research Expertise to Improve Hepatitis C Treatments
HDAP Update p 2
Research Update
Your Support Addresses an Urgent Community Need
Thanks to your support, CRI is addressing an urgent issue in the HIV community:
Hepatitis C.
p3
News and Events p 4-5
An estimated twenty-five percent of individuals infected with HIV in the U.S. are also
infected with the Hepatitis C virus (HCV), an infectious disease of the liver that attacks
the body in similar ways as HIV. Left untreated, HCV can lead to liver failure, liver
cancer, and premature death. Co-infection with HIV more than triples these risks.
Picture the approximately 150 million people globally living with chronic HCV
infection against a backdrop of insufficient and complicated treatments, and
memories of desperate times for people with HIV/AIDS probably come to mind.
Until just recently, individuals undergoing treatment for HCV faced the same
terrifying uncertainty as those with HIV in the 1980s and early 1990s.
CRI researchers continue to play a crucial role in improving HIV treatment regimens
from handfuls of pills taken several times a day—with mixed treatment outcomes—
to the current gold standard of a safe and effective once-daily pill.
Your continued support makes it possible for CRI to lend over two decades of HIV
expertise to research better HCV medications now—so those living with HCV, and
their friends and families, don’t have to spend another decade deciding whether the
benefits of treatment outweigh a drug’s debilitating side effects.
Before HCV is studied in co-infected people (individuals with both HIV and HCV
infection), researchers at CRI and around the world are mastering disease progression
and treatment outcomes in the HCV mono-infected population. CRI is currently
participating in the ION-3 HCV phase 3 trial, which studies an all-oral, fixed-dose
combination tablet consisting of sofosbuvir and ledipasvir, taken once daily for
8–12 weeks, with or without ribavirin (twice daily). Previous study results of similar
combinations are so promising they have resulted in a cure for most. And this is only
the beginning!
Powerful data from studies like these raise as many exciting questions as they answer.
Can we expect to see similar results in the co-infected population? How promising
are long-term results? Can we develop treatments that can be taken even less than
once daily? If an HCV cure is in sight, what does this mean for a cure for HIV? How can
we ensure access to these vital medications for the community in need?
With your help, CRI will continue to investigate these frontline questions and make
HIV and HCV treatments safer, simpler, and more effective than ever before. Because
of you, CRI continues to be at the forefront of community-based research as one
of few independent organizations offering groundbreaking HIV and HCV study
medications and ongoing drug research.
And we couldn’t do it without you! Your support helps bring CRI’s robust research
to the local—and global—communities that depend on it. Together, we can change
the legacy of HIV and HCV.
See page 3 for more information on CRI’s HIV and HCV trials.
HDAP UPDATE
HDAP Helps Patients and Providers Navigate
Affordable Care Act
Massachusetts remains a national leader in ensuring access to HIV-related treatment and care, prevention services,
and health insurance. Expanded Medicaid eligibility, the state’s passage of comprehensive healthcare reform
in 2006, and one of the most comprehensive AIDS Drug Assistance Programs in the country (the Massachusetts
HIV Drug Assistance Program, or HDAP) have not only helped ensure that people remain healthy and productive
members of their communities—they also help prevent new HIV infections.
Despite these successes, recent changes in private and public health insurance programs have made accessing
health services challenging for both patients and providers. Even in Massachusetts, where healthcare reform is
already in place, market forces have impacted the profile of private insurance plans, with trends moving toward
higher out-of-pocket costs, changing deductible requirements, restricted networks, and mail-order prescription
mandates. Staff at state and federal benefits programs are often unable to meet the demands of enrollee requests
for information, application status, and documentation of eligibility determinations.
With the rollout of the Affordable Care Act and its state-based exchanges, the need for clear and concise information
on available insurance plans, their subsidies and tax credits, and enrollment guidance is more crucial than ever.
At the same time, significant state and federal funding cuts have resulted in reductions in training resources and
outreach opportunities for providers. Increased caseloads, case manager staff turnover, and further demands on
available resources present new challenges to the ability of frontline personnel to coordinate access to health
insurance on behalf of their patients.
With these challenges in mind, we at CRI are excited about a new initiative designed to provide coordinated
assistance to healthcare providers for enrolling and retaining their patients in comprehensive healthcare coverage.
Using our expertise in insurance and benefits programs, gained through our management of HDAP, CRI is developing
a resource team to assist both case managers and consumers throughout the state. Working in partnership with the
Office of HIV/AIDS at the Department of Public Health, the Insurance/Benefits Resource Team will address
three objectives:
1. To assist Massachusetts residents living with HIV in accessing available health coverage programs, with
an overall goal of preventing gaps in coverage and reducing reliance on more expensive systems of care;
2. To assist case managers at healthcare sites in helping their patients negotiate and access
comprehensive health insurance coverage and programs, with an overall goal of increasing providers’
knowledge and familiarity with available coverage options; and
3. To reduce the turnaround time of submitted HDAP applications through the triage of general
insurance-related requests for assistance to specialized staff.
Resource team members will present information on public and private insurance programs at HIV-related healthcare
sites and meetings. The team will also provide guidance on insurance eligibility and application procedures.
For more information on the HDAP webinars or other HDAP programs and activities, please contact Craig
Wells, HDAP Program Director at CRI, at 617.502.1734 or cwells@crine.org, or call CRI’s main number
at 617.502.1700.
You’re Invited to Visit Community Research Initiative’s Redesigned Website!
CRI is pleased to announce the launch of our new website (www.crine.org). We designed this website with YOU
in mind. The user-friendly platform makes it easier for you to stay informed about CRI’s latest research findings and
keep abreast of updates from our HIV Drug Assistance Program (HDAP).
We encourage you to bookmark the site, check back
often for updates, and connect with us on Facebook,
Twitter, and YouTube. Your ongoing feedback about the
site is also welcome—with your help, we can reach every
member of our community and continue to share our
integral research.
Visit www.crine.org now and enjoy browsing the
new site. Thank you for helping CRI share our critical
work “from the ground” and online!
R esearch up d ate
R
C
of
Research Trials at CRI
CRI is dedicated to developing new and safer medications for people
living with HIV and HCV. Your support means these types of lifesaving
clinical research trials can open and enroll participants at CRI.
o m m u n i t y
e s e a rc h
I
n i t i a t i v e
new england
Board of Directors
Jeremy T. Holman, PhD
President
Jonathan B. Goode
Vice President
START
The START (Strategic Timing of Antiretroviral Treatment)
study will answer the question, “When should I start taking HIV
medication?” Currently guidelines are not consistent as to when
the best time to start treatment would be. Some practice guidelines
state that it is okay to begin medication when a person’s CD4 count
reaches 350, while others suggest offering treatment immediately
no matter how high the CD4 count is at the time of diagnosis. START
is a large, definitive study to determine whether individuals should
begin treatment with high CD4 counts (above 500) or whether it is
better to wait to start for a CD4 count of around 350.
STR GFR
The STR GFR study evaluates the effect of an experimental singletablet regimen consisting of elvitegravir/cobicistat/emtricitabine/
tenofovir alafenamide (E/C/F/TAF) for HIV-positive individuals with
mild to moderate impairment of kidney function. The study will test
how well this combination works – and how safe it is – both in those
who have never been on treatment and those who are treatmentexperienced. Because kidney impairment is a fairly common
complication in HIV-positive individuals, this single tablet has the
potential to become an important medication in HIV therapy.
ION 3
The ION 3 study is a phase 3 clinical trial for participants with
genotype 1 Hepatitis C, without cirrhosis (irreversible scarring of the
liver), who have never received treatment for Hepatitis C.
The purpose of this study is to evaluate the safety, tolerability, and
antiviral efficacy of Sofosbuvir/Ledipasvir (FDC) with or without
ribavirin. This study is investigating an oral, direct-acting antiviral
experimental study regimen that is half the number of weeks of
standard treatments.
For more information about clinical trials at CRI, visit our website at
www.crine.org or call our research team at 617.502.1700.
Frank A. Ribaudo
Treasurer
Paul Moreno
Clerk
John W. Devlin, PharmD
Anne Habel
Alfredo Hernandez
Lisa A. Pintchman
Scott Sylvia, DO, MBA
Susan Ulrich, JD
Ann Webster, PhD
Leadership Council
Jon Appelbaum, MD
David Aronstein
Robert Beck
Douglas M. Brooks, MSW
Donald Butterfield, MD
Mark Christofi
Carolyn Crowley
Jonathan Crutchley
Glenn Daidone
Victor DePoalo
Richard Dickinson
Douglas Dolezal
Dixie-Lee Esseltine, MD
Clive Godwin
Joel Goldstein, PhD
Sharon Gray
Sheila Hussey
Larry Hyer
Lenore Jackson-Pope, RN, ACRN
Bobby Kelley
Tim Martinez, DMD
John Mazzullo, MD
Ellen Morris McCann
Michael McGuill, DVM, MPH
Jim Morgrage
Paul Ross, EdD
Sandy Sheble-Hall, RN, ACRN
Gregory Welch
Executive Director
Julie K. Marston, MPH
Deputy Executive Director/HDAP
Program Director
Craig R. Wells, MSL
Director of Research
Calvin J. Cohen, MD, MSc
Director of Development
Deb Shapiro
Like CRI on Facebook,
follow us on Twitter,
and watch our
YouTube videos.
CRI’s Mission:
To lead the way in clinical
HIV/AIDS research and to ensure
access to lifesaving drugs
to those in need
ACCESS Editors
Sanju Poudel
Leah Wohl-Pollack
CRI ACCESS
3
Ne w s a n d E V E N T S
Red Hot Record-Breaker!
You Raised $75K+ for HIV and Hepatitis C Research
Thank you for making our 10th annual summer party a red hot success! Over 250 supporters celebrated a decade
of groundbreaking research at the iconic Red Inn in Provincetown on July 20, and you raised over $75,000 for HIV
and Hepatitis C research! It was a beautiful day to celebrate with new and dear friends and to enjoy delightful
artwork, delicious brunch, and a serene waterfront at a stunning venue. We hope you will join us next summer to
commemorate another year of breakthrough research.
Endless thanks to all who made this event possible:
Generous sponsors and benefactors
The Red Inn; Online Buddies/MANHUNT; Cal Cohen; Eastern Bank; Gary
Reinhardt; Kenneth Freed & Company/Freed Investment Group; Victor’s;
Larry Hyer; Crane McCune & Ron Chapman; Ann Webster; Dickinson Lab;
Scott Allegretti, DDS; Richard Bankhead & Kemper Thompson; Beachfront
Realty/Jon Goode & Bill Farmer; Brian Farley & Ron Alose; 5 Star Travel
Services; Julie Goodridge; Justice Resource Institute; Ken Lima & Mark Sacco;
John Spencer; Donald Vaughn & Lee Ridgway; and Michael Wallerstein.
Host committee
Douglas Brooks; Ron Chapman & Crane McCune; Roberto
Caldera; Marc Croteau; Jamie Curtis; Carolyn & Michael
Crowley; Amit Dixit; Bill Farmer; Kenn Freed; Don Harpin;
Larry Hyer; Bobby Kelley & Eddie Luis; Fred & Steven
Latasa-Nicks; Sal Malafronte; Matt Marcotte & Mario
Pinho; Philip Mossy & Tiago Pegorim; Michael O’Hagan &
Mark Gallant; Peter Portney; Paul Rodrigues & Matthew
Trento; Paul Ross; Angela Russo & Sandy Rabb; Rich Scott;
and Courtney Spitz & Miriam Gallardo.
Gracious hosts
Omar Sharif, Jr.; Jon Goode & Cary
Raymond; Doug Dolezal & Greg
Welch; Philip Mossy, Sean Burke, &
David Silva; and Victor DePoalo.
The talented artists and auction donors
Chris McCarthy, Executive Director, Provincetown
Art Association Museum; Greg Welch; Joe Fiorello;
Paul Davis Jones; Doug Dolezal; Deborah Kerr;
Johniene Papandreas; Adam Peck; Jen Rumza; Lucy
Cobos; Jon Goode & Cary Raymond; Paul Moreno;
and Philip Mossy.
And hats off to the Hat Sisters for being such
incredible examples in heels!
Thanks also to our dedicated staff representatives—we appreciate all you do every day: Julia Green; Nathan
Paquet; Julie Marston; Karen McLaughlin; Sanju Poudel; Deb Shapiro; Claudia Stumpf; Joanne Delaney; and
Craig Wells.
Thanks again for making this summer a record-breaker for HIV and Hepatitis C research!
Ne w s a n d E V E N T S
Boston Still Strong – Thanks to You!
Harbor to the Bay Ride 11: By the Community, for the Community
On September 21, 2013, as 300 riders, 200 crew members, and countless volunteers, donors, and sponsors, you
gathered together to stand up to HIV/AIDS. In memory of those lost and in honor of friends and family still with us,
you took to your bikes, cheered one another on, and have raised nearly $450K to date!
One hundred percent of every dollar raised from this volunteer-run event goes directly to local HIV/AIDS beneficiaries
like Community Research Initiative. And because this community doesn’t ever stop spinning its wheels, all of our
hardworking teams, riders, and crew members are continuing to fundraise through the end of November to reach
H2B’s $500K goal!
If it weren’t for the passion, sweat, and year-round efforts of this dedicated community, none of this would be possible.
You can be a part of the incredible story that is transforming our community by making a donation to TEAM CRI
today at www.harbortothebay.org. Donating to TEAM CRI will ensure that one hundred percent of your
donation goes directly to CRI’s research.
Thank you for making Ride 11 a breakaway success! Contact Sanju at 617.502.1726 or spoudel@crine.org for
more information or to sign up for Ride 12 on September 20, 2014!
peace, love & cycling
Lifesaving Research from Boston to Around the Globe
You Help CRI Contribute to International Efforts to End the AIDS Epidemic
Thanks to your support, Research Director
On September 27, the CRI research team
Dr. Cal Cohen shared CRI’s research at the
attended and supported the 8th Annual
world’s largest open scientific conference
National Conference on HIV/AIDS and
on HIV/AIDS. The 7th International AIDS
Aging, of which Dr. Cal Cohen is a committee
Society Conference on HIV Pathogenesis,
member. The conference is hosted by the
Treatment and Prevention was held in
New England Association on HIV Over Fifty
Kuala Lumpur, Malaysia.
(NEAHOF), and this year, over 400 clinicians,
CRI Executive Director Julie Marston
Dr. Cohen presented a poster on the STaR
consumers, and public health advocates
introduced physician and HIV expert Dr.
gathered in Boston for a day of lectures,
Applebaum at the NEAHOF conference
community
in September.
study, which compared two single-tablet
regimens for safety and efficacy. He also
presented research that compared Stribild, a
recently approved single-tablet quad regimen,
with Atripla, an established three-drug singletablet regimen.
discussion,
partnerships,
and
networking.
CRI ACCESS
5
F R I E ND S O F C R I
Thanks for supporting us! You make CRI’s lifesaving work possible. The following donors contributed
to our important efforts between April 30 and September 30, 2013:
Joseph Agostini
Scott Allegretti, DDS
Douglas Amarelo
Jon Appelbaum, MD & William Morowski
Bryan Armstrong
Brian Back
Guy Backlund
Richard Bankhead, DDS & Kemper Thompson
Michael Barnum
Rusdael Barros & Scott Andonian
Walter Batt & Bob Koherr
in honor of Larry Hyer
Bradley Bechok
James Bennette
David Berarducci
Anne & Jacob Berlin
in memory of John B. Morris
Mark Bombara
Jane Boyd & Dr. Peter Koeppe
in memory of Anne B. Morris, MD
Douglas Brooks
Michael Burke
in memory of Nick Houpis
Nicholas Calabrese
John Carmilia & J.H. Miner
Robert Caro
David Casey
Rich Caswell & Steve Martin
Ronald Chapman & Crane McCune
Dominic Cioffoletti
Stewart Clifford Jr.
Lucy Cobos
Calvin Cohen, MD, MSc
Harry Collings & Daniel Moon
Greg Connors
Michael Constantinides
Andrea Cordova
Kevin Coughlin
Teresa Cromwell
Jonathan Crutchley
James Curtis
David Datz & Jim Mauro
Paul Davis Jones
Joanne Delaney, RN
Joseph DeMartino
Victor DePoalo
Stephen Derby & Joe Geiermann
in memory of Nick Houpis
Dorian DesLauriers & Jorge DesLauriers
Patrick Devine
John Devlin, PharmD & Marc Hall
Richard Dickinson
David DiRocco
John Dobija
Jean-Cosme Dodart
Patrick Dolan
in honor of Tim Riordan
Doug Dolezal & Greg Welch
Lisa Drapkin & Debbie Lewis
Tim Dudley
Kia Earp
Johannes Eijmberts
Brian Farley & Ron Alose
William Farmer
Laurie Ferrari
Joe Fiorello
Robert Flagg
Emily Flax & Carol Neal
Kenneth Freed, CPA
Tony Fuccillo
Andrew Fullem
Lucas Garofalo
Therese Giove
Martha Gladue & Margaret Valenti
Joel Goldstein, PhD & Reed Goodman
Ana Gomes
I. Luis Gomez
Jonathan Goode & Cary Raymond
Julie Goodridge
Michael Gosselin & Jonathan Cruz
Deb Graeber
Julie Gray & Andrea Still Gray
Robert Greene
Timothy Grobleski
Lisbeth & Lyle G. Hall
in honor of Sandy Sheble-Hall
Gabrielle Hanna & Marcy Feller
Roger Hanzes
Don Harpin
Robert Hass
Craig Hazenfield
Jeremy Holman, PhD & Marcus Matic
Derek Howe
Lawrence Hyer
Lenore Jackson-Pope, RN, ACRN
Jay Jakubowski, DVM & Shawn Nighingale
John Chadwick Johnson & Anthony Abbatiello
Robb Johnson
Wendy Jolles & Suzanne Lowell
John Noffo Kahn
Eugene Kelly
Deborah Kerr
Gary Kon
Joseph LaMotta
Marijean Lauzier & Jane Hiscock
William Lawrence Jr.
in memory of Anne B. Morris, MD
Kenneth Lawton
Timothy Leahy
Noele Lee
Suzanne Lee
Laurie Leibowitz
Tom Lewis
Kenneth Lima & Mark Sacco
Mark Lippolt & Scott MacDonald
in honor of Jon Goode
Leo Louden Jr.
Lisa Loveland
Edmund Luciano
Ann Maguire & Harriet Gordon
Matt Marcotte & Mario Pinho
Julie Marston, MPH
Elaine Matisoff
in memory of Martin A. Goldman
Guy Matsuda & Philip Allessio
Chris McCarthy
Richard McCarthy
David McChesney
in honor of Kenn Freed
Sean McConnell
Hirschel McGinnis
Michael McGuill, DVM, MPH & Jonathan Scott
Dermot Meagher
Loretta Moreno
Paul Moreno
Steven Moskowitz
Daniel Mullin
Rick Murray & Bill Dougal
Karen Nash
Steve Nason
Tim O’Connor & John Gray
Michael O’Hagan & Mark Gallant
Matthew O’Hurley
Shawn O’Neill
Michael Palmer
Robert Panessiti & Michael Hogan
Frank Pantano & Eddie Conroy
Richard Parritz
Leslie Parsons
Adam Peck
Theodore Pietras
Lisa Pintchman Rogers & Jay Rogers
Michael Poirier
Peter Portney
Anton Ramus
Gary Reinhardt
Frank Ribaudo & Joe Posa
Glenn Rigoff
Michael Roberts
Nirka Rosa
Paul Ross, EdD
Dennis Roy
Jen Rumza
Roger Sametz & DuncanRhys Liancourt
Paul Scannell
Alan & Karen Shapiro
Tim & Deb Shapiro Suydan
John Sharp & Richard Lacasse
Lincoln Sharpless & Robin Evans
Oren Sherman & Richard Miller
Richard Silverman
Edward Smith
Marcia Smith
Ted Smith
John Spagnoletti
John Spencer
Joe Spinale
Courtney Spitz & Miriam Gallardo
Dan Spring
Larry Steinbach
Vincent Stephens
Todd Stevenson
Meg Stewart
Michael Stone
in honor of Ann Webster, PhD
Peter Tenggren & Warren Mitchell
Elizabeth Tepper
Steven Tromp
Oriana Van Daele
Donald Vaughan & Lee Ridgway
Robert Vitale
Fiat Vongpunsawad
Michel Wallerstein
Elizabeth Warner
Kim Watson & Keith Masters
Stephen Watson
in memory of Alan Matheaus
Ann Webster, PhD
Todd Westrick
Laurence Young
Joseph Zibrak
Businesses, Organizations and Foundations
Abbott Laboratories
American Tower Corporation
BNY Mellon Community Partnershp
Community Health Charities
Community Health Charities of New England
Eastern Bank
5 Star Travel
Gifford Family Foundation
Gilead Sciences
Harbor to the Bay Ride
Justice Resource Institute
Merck & Company, Inc.
Myrtle Baptist Church
Online Buddies/MANHUNT, Inc.
Provincetown Art Association Museum
The Red Inn
State Street Foundation
Victor’s
Every effort has been made to ensure the accuracy of this list.
We apologize for any errors and ask that you call our Development Office at 617.502.1710 or email corrections to dshapiro@crine.org.
Make a Bequest to CRI
You Can Give a Lasting Gift of Health
You can help CRI today and provide a healthier future for those living with HIV
and Hepatitis C. Donating to CRI through a bequest in your will ensures the
development of safer, more effective HIV and Hepatitis C medications and access
to vital treatment.
Check with your attorney or financial advisor for more information on how to
leave a lasting impact on the HIV and Hepatitis C community.
For more details, contact Deb Shapiro at dshapiro@crine.org or
617.502.1710.
Other simple giving options include:
• Naming CRI as the beneficiary of an
IRA, SEP, or other retirement account
• Using part or all of the proceeds of a
life insurance policy to support CRI
• Designating CRI as the beneficiary of
bank and brokerage accounts or
other assets
L E A Dership g ivi n g
Leadership Donors help sustain CRI’s mission. You allow us to:
• initiate unique and independent CRI investigator-led HIV and Hepatitis C research studies
• broaden our research network to answer difficult research questions quickly
• expand access to vital HIV/AIDS and Hepatitis C treatment and drug trials to traditionally
underserved communities
• leverage the critical results from our community-based research to ensure better HIV and Hepatitis C treatment
options and drug regimens worldwide
CRI’s 1500 Fund is the sustaining gift program for annual donors of $1,500 or more:
•Abbott
•Beachfront Realty
•Ben Baker & the Baker Family
•Mitchell Baker & Thom Egan
•Andrew M. Fullem
•Ambassador Rufus Gifford
& Stephen DeVincent
in honor of Cal Cohen, MD
•Larry Basile
•Jon Goode & Cary Raymond
•Donald E. Butterfield, MD
•Julie Goodridge
•Jim Bracciale & Rick Kestler
•Ronald Chapman & Crane McCune
•Community Health Charities
•Dorian & Jorge DesLauriers
•Bernard Dreiblatt
•John Chadwick Johnson & Anthony
Abbatiello
•Dixie-Lee Esseltine, MD & Debbie Taylor
•Brian Farley & Ron Alose
•5 Star Travel
•Kenneth Freed/Kenneth Freed &
Company/Freed Investment Group, LLC
•Reed Goodman & Joel Goldstein, PhD
•Justice Resource Institute
•Seth Grosshandler & Kim Wainwright
•Lisbeth & Lyle G. Hall
in honor of Sandy Sheble-Hall
•Roger Hanzes
•Craig Hazenfield
•Lawrence R. Hyer/Lawrence R. Hyer Fund:
A Fidelity Gift Fund Donor-Advised Fund
•Robert Kelley & Eddie Luis
•Sean McConnell
•Paul Moreno
•William Jacob Murray III, DMD
•Myrtle Baptist Church
•Novartis US Foundation
•Scott Popkowski & Joseph Smith
•Provincetown Art Association
& Museum (PAAM)
•Gary Reinhardt
•Frank Ribaudo & Joe Posa
•Michael Stone
•Peter Tenggren
•Donald E. Vaughan & Lee Ridgway
•Victor’s
•Ann Webster, PhD
•Matt Marcotte
•Wendy Marston
CRI’s Research Circle honors all of you who take a leadership role in supporting CRI’s critical efforts with an
annual donation of $5,000 or more:
•Bob Beck
•Discovery Communications
•John J. Noffo Kahn
•Calvin Cohen, MD, MSc
•Gilead Sciences
•The Red Inn
•Bessent-Freeman Family
•Dickinson Labs
•Jonathan Crutchley
•Victor DePoalo
•Eastern Bank
•Harbor to the Bay Ride
•Ian Lekus
•Online Buddies/MANHUNT, Inc.
•Soros Fund Charitable Foundation
•Michael Williams
Every effort has been made to ensure the accuracy of this list.
We apologize for any errors and ask that you call our Development Office at 617.502.1710 or email corrections to dshapiro@crine.org.
Keep Your Wheels Spinning for Research!
Julia’s “Saab” Story Takes a Sweet Turn
CRI Research Operations Manager Julia Green recently donated her beloved
1986 Saab to CRI, saying, “She may no longer be roadworthy, but she can still
make a difference by supporting CRI’s lifesaving HIV and Hepatitis C research.”
Do you have an old vehicle taking up space in your driveway too? Donate it to
CRI at no cost to you, and receive a one hundred percent tax deduction!
CRI’s vehicle donation program covers all the logistics. Just visit the giving section
of our website, complete the CARS donation form, and we’ll take care of the
rest—it’s that easy!
CRI ACCESS
7
You Make Lives Better – You Can Contribute to CRI in Many Ways
· Direct, Unrestricted Donations Place your gift in the general fund and support the day-to-day activities of CRI.
Your gifts of cash, stocks, or securities help CRI conduct research that saves lives.
· Matching Gifts You can maximize your gift if you (or a member of your family) qualify for corporate matching funds.
Please check with your company to see if they participate in a matching funds program, and include a matching gift form
for added support to CRI.
· Gifts in Honor or Gifts in Memory Make a gift in honor of an individual, to celebrate a special occasion, or in
memory of a deceased friend or family member. CRI will notify whomever the donor designates.
· Gifts of Bequests or Planned Giving CRI is grateful for bequests via wills and planned giving arrangements. Please
consider naming CRI the beneficiary of an IRA, retirement fund, SEP, or insurance policy. We encourage you to discuss
your giving options with your lawyer or other financial representative to determine how you can provide for the future
growth of CRI while maximizing your tax benefits.
A donation envelope is enclosed for your convenience.
For more information, please contact Deb Shapiro at 617.502.1710 or dshapiro@crine.org
Donate Online
Just go to www.crine.org and click
“I ride because I
love my brother
Ben.”
Riders take on 68 to 125 miles to help
end the AIDS epidemic. Watch their
inspiring stories!
our lifesaving research
our global impact
your critical support
o m m u n i t y
R
e s e a rc h
I
n i t i a t i v e
CRI
HDAP
38 Chauncy Street
Suite 500
Boston, MA 02111-2301
tel: 617.502.1700
fax administration: 617.502.1701
fax research: 617.502.1702
toll free: 888.253.2712
tel: 800.228.2714
fax: 617.502.1703
of New England
email: info@crine.org
www.crine.org
Design:
C